Although the safety of this novel therapy has been evaluated, there remains a paucity of data on recurrence outcomes. 9 Historically, local recurrence (LR) rates following thermal ablation have ranged from 3% to 30%. 14 However, current reports on the effectiveness of IRE have predominantly included small sample sizes with short followup intervals. [15] [16] [17] [18] [19] Herein, we present the largest series to date assessing LR patterns following IRE for primary and secondary hepatic malignancies and discuss prognostic factors associated with LR.
| METHODS
We performed a retrospective review of a prospectively maintained Patients treated by a percutaneous approach were not included. All clinicopathologic data were obtained following approval from the Institutional Review Board. The NanoKnife (Angiodynamics) IRE device was used in all patients; of which the technical details have been previously reported by our group. 9 
| Patient selection
All patients had primary or secondary hepatic malignancies and were staged preoperatively with contrast enhanced computed tomography (CT) imaging and/or magnetic resonance imaging (MRI) of the chest, abdomen, and pelvis. Select patients also had positron emission tomography (PET) obtained pre-operatively. All lesions precluded resection of thermal ablation due to their peri-vascular location (proximity to hepatic vein or portal pedicle). In the operating room, a laparotomy was performed and IRE was completed either alone or in combination with another procedure(s). One patient had a repeat IRE for a local recurrence and this lesion was excluded from analysis. At the time of operation, the size of the ablation zone was determined/ measured by a NanoKnife algorithm using the distance between the active ends of the probes and the power settings. Size data were then entered into the operative report.
| Patient follow-up
All patients were seen in follow-up after discharge from the hospital.
Cross-sectional imaging was obtained at variable times, typically three times yearly for the first 2 years and then bi-annually if disease was stable during the 3-5 years following surgery. As previously reported, complications that developed during the peri-operative period were prospectively recorded into the MSKCC surgical secondary-events program (SSE), which utilized a classification system similar to ClavienDindo.
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Local recurrence was denoted by recurrence of tumor in an area of previously documented complete ablation as determined by a MSKCC radiologist on a post-procedure scan. Specifically, we defined local recurrence as abnormal enhancement at the periphery, increasing size/ parenchymal density of an ablation site on post-procedure contrast enhanced imaging or increased PET avidity at the ablation zone site.
| Factors of local recurrence assessed by univariate analysis
The following variables were assessed: age at surgery, body mass index and pleural effusion (1/40, 3%), as depicted in Table 3 . Complications specific to IRE (classified per patient) included intra-operative arrhythmia 1/40 (2.5%), post-operative hepatic vein perfusion defect 1/40 (2.5%) and post-operative hepatic vein thrombosis 1/40 (2.5%).
In those patients who had IRE performed alone (14/77, 18%), one patient experienced a peri-hepatic hematoma (1/14, 7%). bilirubin levels (P = 0.07) and age at surgery (P = 0.08) approached significance, (Table 4) . LR was not found to be associated with Couinaud segmental location, tumor size, distance to major vasculature, proximity to major bile ducts, or the administration of systemic therapy.
| Local recurrences

| Institutional comparison of IRE to thermal ablation
Our LR findings for IRE were similar to LR results in a previously reported matched group of patients who underwent RFA or MWA at our institution. 2 The CumI of LR following IRE (13.4%, 95%CI: 7. Additionally, it is now well known that proximity to major vasculature is an impediment to thermal ablative therapies due to the heat sink effect, which can cause a drop in treatment efficacy below 50%. 15, 22, 23 Additionally, thermal damage to surrounding structures, in particular vessels or bile ducts, substantially increases the risks of peri-operative complications. IRE on the other hand, may be able to overcome these limitations imposed by thermal ablation. Clinical studies have added weight to the above theory that IRE produces discriminate cell death, leaving vascular or biliary structures intact. 7 In the COLDFIRE-1 trial, investigators prospectively IRE ablated 10 peri-vascular hepatic malignancies which were then resected 1 h later. In doing so, they demonstrated cell death of the ablated tumors within 1 h after IRE, however, large vascular and ductal structures within the ablation zone remained intact. 7 IRE may ultimately allow for the treatment of liver tumors deemed unresectable or ineligible for other focal ablation techniques due to their peri-vascular location and should, therefore, be added to the armamentarium of providers caring for patients with primary or secondary liver cancers. 24 In agreement with our findings, others have also reported acceptable LR rates following IRE for hepatic malignancies (Table 5 ).
In an analysis of 18 lesions treated with IRE, at a median follow-up of 18 months, 72% of lesions were completely ablated. 17 Moreover, the authors found a 93% success rate for lesions ≤3 cm with a local recurrence-free period of 18 ± 4 months. 17 Similarly, Cannon et al reviewed 44 hepatic lesions treated with IRE and found a local recurrence free survival (LRFS) of 60% at 1 year. 16 However, in lesions <3 cm, the LRFS at 1 year increased to 98%. 16 Following suit, Eisele et al reported on 13 hepatic lesions with a LR of 21% following IRE and again found lesion size to be the best predictor of LR. 19 A possible reason for the higher recurrence with tumors larger than 3-4 cm is the number of probes required to treat these larger lesions. 16 As instructed by the manufacturer, a 3 cm tumor is the upper limit which can be treated with a 3 probe array and the authors concluded that larger probe arrays cannot be placed with the precision necessary to treat larger tumors. 16 On the contrary, Hosein et al reported on 29
patients in which 58 hepatic lesions were treated with IRE. 18 At a median follow-up of 11 months, they found six cases of partial response (21%), seven cases of stable disease (25%), and five cases of progressive disease (18%). 18 However, unlike the previous studies presented, the sizes of the treated lesions were not associated with outcome differences. 18 We postulate that a potential reason for a failure to show tumor size associated with LR relates to our median tumor size of 1.3 cm. Specifically, only four lesions were over 3 cm; therefore, suggesting our database did not contain enough larger tumors to show an association with size and LR. On the other hand, the ablation zone size was measured by the surgeon at the time of surgery and may be a surrogate for size since we strived for a minimum of a 1 cm ablation margin.
Furthermore, Niessen et al reported a LR of 29.2% following the treatment of 48 hepatic lesions. 15 Similar to the previously presented studies, when the lesions were dichotomized by tumor density (surrogate for size), those <5 cm 3 had a LR of 9.7% as compared to lesions >5 cm 3 who saw a LR of 65%. 15 As hypothesized following preclinical models, LR did not differ significantly between lesions that were and were not adjacent to large vessels or bile ducts. 15 Interestingly and synonymous to our results, the authors found BMI to predict LR. 15 We postulate that a fatty liver may cause a decrease in electrical conductivity. This conductivity differential may, therefore, contribute to a decrease in the efficacy of IRE; similar to the fact that electrical conductivity is higher within cirrhotic tissue. 25 Furthermore, ultrasound guided probe placement is more problematic in the obese patient due to hyperechoic ultrasound images secondary to their fatty liver.
One question that remains to be answered is how recurrence rates compare between IRE and thermal ablative therapies. Unfortunately, due to the fact that IRE is typically reserved for lesions which preclude thermal ablation, an unbiased, matched, direct comparison was not possible. However, we evaluated our IRE results in the context of patients who previously underwent RFA or MWA at our institution (data not shown). 2 In doing so, we found IRE to have similar LR rates to the thermal technologies. Although the study period and follow-up time differed between cohorts and biases inherent in lesion selection are present, based on these LR's, we suggest IRE may have an acceptable LR rate as compared to thermal ablative therapies.
With respect to safety, it should be mentioned that 35% of our patients experienced complications. However, we do not believe this represents an accurate percentage of IRE-related complications since 82% of our patients had IRE performed in combination with another
procedure. Yet, there were IRE-specific complications including one hepatic venous perfusion defect and a left hepatic vein thrombosis.
The hepatic venous perfusion defect was identified on CT imaging performed 1 week following IRE and was resolved by the following CT Moreover, Silk et al retrospectively assessed biliary complications after IRE ablation of 22 hepatic tumors in the immediate proximity of major bile ducts. 27 They found no major biliary complications. 27 Overall, as previously published, IRE remains a safe modality with peritumoral tumor complication rates.
Although we are filling a gap within the current literature, we acknowledge several limitations to our work. First, this was a retrospective analysis with a small sample size which included heterogenous pathology and systemic treatment. Second, the identification of LR was based off of non standardized crosssectional imaging modalities at non-controlled intervals. This is a clear limitation. Moreover, the limited number of LR events restricted our ability to perform multivariate analyses or build risk models. Lastly, our use of hepatic arterial infusional pump therapy should be mentioned as a confounding factor; for as compared to other groups and historical controls, we utilized pump therapy in a higher percentage of patients. Therefore, we present our work as hypothesis generating, since concrete clinical conclusions cannot be drawn from our data.
Despite these limitations, the current study does identify important themes. In particular, it is currently the largest series with 
| CONCLUSION
The role of IRE within the context of expanding local and regional treatment options for hepatic malignancies is currently being defined.
Due to the low peri-tumoral tissue toxicity, the lack of a heat sink effect and acceptable LR rates offered by IRE, it may be a beneficial ablative technology for peri-vascular hepatic malignancies which otherwise preclude resection or thermal ablation. IRE should, therefore, be included within multi-disciplinary discussions of the treatment of peri-vascular primary and secondary hepatic metastases.
Moreover, IRE may allow otherwise unresectable patients the opportunity at resection or two-stage hepatectomy. Future studies assessing the most accurate imaging modality to identify recurrence and strategies that utilize IRE as an adjunct to systemic treatment may prove beneficial.
ACKNOWLEDGMENT
This study was supported in part by NIH/NCI P30 CA008748 (Cancer Center Support Grant). 
